Cobicistat/darunavir

Drug Profile

Cobicistat/darunavir

Alternative Names: Darunavir/cobicistat; G 006; Prezcobix; Rezolsta

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Gilead Sciences; Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen R&D Ireland
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules; Sulfonamides
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 31 Jan 2017 Phase-I clinical trials in HIV-1 infections (In adolescents, In children) in USA (PO) (NCT02993237)
  • 20 Dec 2016 Janssen plans a phase I trial for HIV-1 infections (In adolescents) in USA (NCT02993237)
  • 12 Oct 2016 Launched for HIV-1 infections (Combination therapy) in France, Spain, United Kingdom, Sweden, Portugal, Germany, Italy, Netherlands, Norway (PO) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top